TY - JOUR
T1 - Noninvasive diagnosis of nonalcoholic fatty liver disease andquantification of liver fat using a new quantitative ultrasound technique
AU - Lin, Steven C.
AU - Heba, Elhamy
AU - Wolfson, Tanya
AU - Ang, Brandon
AU - Gamst, Anthony
AU - Han, Aiguo
AU - Erdman, John W.
AU - O'Brien, William D.
AU - Andre, Michael P.
AU - Sirlin, Claude B.
AU - Loomba, Rohit
N1 - Publisher Copyright:
© 2015 AGA Institute.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Background & Aims: Liver biopsy analysis is the standard method used to diagnose nonalcoholic fatty liver disease (NAFLD). Advanced magnetic resonance imaging is a noninvasive procedure that can accurately diagnose and quantify steatosis, but is expensive. Conventional ultrasound is more accessible but identifies steatosis with low levels of sensitivity, specificity, and quantitative accuracy, and results vary among technicians. A new quantitative ultrasound (QUS) technique can identify steatosis in animal models. We assessed the accuracy of QUS in the diagnosis and quantification of hepatic steatosis, comparing findings with those from magnetic resonance imaging proton density fat fraction (MRI-PDFF) analysis as a reference. Methods: We performed a prospective, cross-sectional analysis of a cohort of adults (N= 204) with NAFLD (MRI-PDFF, ≥5%) and without NAFLD (controls). Subjects underwent MRI-PDFF and QUS analyses of the liver on the same day at the University of California, San Diego, from February 2012 through March 2014. QUS parameters and backscatter coefficient (BSC) values were calculated. Patients were assigned randomly to training (n= 102; mean age, 51 ± 17 y; mean body mass index, 31 ± 7 kg/m2) and validation (n= 102; mean age, 49 ± 17 y; body mass index, 30 ± 6 kg/m2) groups; 69% of patients in each group had NAFLD. Results: BSC (range, 0.00005-0.25 1/cm-sr) correlated with MRI-PDFF (Spearman ρ= 0.80; P < .0001). In the training group, the BSC analysis identified patients with NAFLD with an area under the curve value of 0.98 (95% confidence interval, 0.95-1.00; P < .0001). The optimal BSC cut-off value identified patients with NAFLD in the training and validation groups with 93% and 87% sensitivity, 97% and 91% specificity, 86% and 76% negative predictive values, and 99% and 95% positive predictive values, respectively. Conclusions: QUS measurements of BSC can accurately diagnose and quantify hepatic steatosis, based on a cross-sectional analysis that used MRI-PDFF as the reference. With further validation, QUS could be an inexpensive, widely available method to screen the general or at-risk population for NAFLD.
AB - Background & Aims: Liver biopsy analysis is the standard method used to diagnose nonalcoholic fatty liver disease (NAFLD). Advanced magnetic resonance imaging is a noninvasive procedure that can accurately diagnose and quantify steatosis, but is expensive. Conventional ultrasound is more accessible but identifies steatosis with low levels of sensitivity, specificity, and quantitative accuracy, and results vary among technicians. A new quantitative ultrasound (QUS) technique can identify steatosis in animal models. We assessed the accuracy of QUS in the diagnosis and quantification of hepatic steatosis, comparing findings with those from magnetic resonance imaging proton density fat fraction (MRI-PDFF) analysis as a reference. Methods: We performed a prospective, cross-sectional analysis of a cohort of adults (N= 204) with NAFLD (MRI-PDFF, ≥5%) and without NAFLD (controls). Subjects underwent MRI-PDFF and QUS analyses of the liver on the same day at the University of California, San Diego, from February 2012 through March 2014. QUS parameters and backscatter coefficient (BSC) values were calculated. Patients were assigned randomly to training (n= 102; mean age, 51 ± 17 y; mean body mass index, 31 ± 7 kg/m2) and validation (n= 102; mean age, 49 ± 17 y; body mass index, 30 ± 6 kg/m2) groups; 69% of patients in each group had NAFLD. Results: BSC (range, 0.00005-0.25 1/cm-sr) correlated with MRI-PDFF (Spearman ρ= 0.80; P < .0001). In the training group, the BSC analysis identified patients with NAFLD with an area under the curve value of 0.98 (95% confidence interval, 0.95-1.00; P < .0001). The optimal BSC cut-off value identified patients with NAFLD in the training and validation groups with 93% and 87% sensitivity, 97% and 91% specificity, 86% and 76% negative predictive values, and 99% and 95% positive predictive values, respectively. Conclusions: QUS measurements of BSC can accurately diagnose and quantify hepatic steatosis, based on a cross-sectional analysis that used MRI-PDFF as the reference. With further validation, QUS could be an inexpensive, widely available method to screen the general or at-risk population for NAFLD.
KW - AUC
KW - Biomarker
KW - Chronic liver disease
KW - Diagnostic
KW - Hepatic steatosis
KW - Magnetic resonance imaging
KW - Nonalcoholic steatohepatitis
UR - http://www.scopus.com/inward/record.url?scp=84931574623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931574623&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2014.11.027
DO - 10.1016/j.cgh.2014.11.027
M3 - Article
C2 - 25478922
AN - SCOPUS:84931574623
SN - 1542-3565
VL - 13
SP - 1337-1345.e6
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 7
ER -